Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Debt to Equity (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Debt to Equity for 5 consecutive years, with $0.08 as the latest value for Q3 2025.

  • For Q3 2025, Debt to Equity rose 4.74% year-over-year to $0.08; the TTM value through Sep 2025 reached $0.08, up 4.74%, while the annual FY2024 figure was $0.09, 64.56% up from the prior year.
  • Debt to Equity hit $0.08 in Q3 2025 for Kezar Life Sciences, down from $0.09 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.09 in Q4 2024 and bottomed at $0.03 in Q2 2022.
  • Average Debt to Equity over 5 years is $0.06, with a median of $0.05 recorded in 2021.
  • Year-over-year, Debt to Equity fell 25.44% in 2022 and then surged 65.19% in 2024.
  • Kezar Life Sciences' Debt to Equity stood at $0.05 in 2021, then dropped by 25.44% to $0.04 in 2022, then soared by 47.32% to $0.05 in 2023, then surged by 64.56% to $0.09 in 2024, then decreased by 9.23% to $0.08 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.08, $0.09, and $0.09 for Q3 2025, Q2 2025, and Q1 2025 respectively.